<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271868</url>
  </required_header>
  <id_info>
    <org_study_id>IB1001-02</org_study_id>
    <nct_id>NCT01271868</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B</brief_title>
  <official_title>Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptevo BioTherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptevo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study's Primary Objective is to evaluate the pharmacokinetics, safety (acute effects
      associated with infusions, and inhibitor development) and efficacy (breakthrough bleeding and
      control of hemorrhaging during prophylaxis) of IB1001 in previously treated pediatric
      subjects with hemophilia B.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">November 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Infusions Required for Bleed Control</measure>
    <time_frame>Treatment Study: at least 50 ED (approximately 6 months); actual mean subject duration: 39.7 ± 12.4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (0-inf)</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration (Max)</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Steady State)</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleed Rate</measure>
    <time_frame>Treatment Study: at least 50 ED (approximately 6 months); actual mean subject duration: 41.7+/- 11.7 Months</time_frame>
    <description>Measure was assessed during the Treatment Study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>IB1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IB1001</intervention_name>
    <arm_group_label>IB1001</arm_group_label>
    <other_name>Recombinant factor IX</other_name>
    <other_name>IXINITY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject's parent or legal guardian must give written Institutional Review Board
             (IRB)/Independent Ethics Committee (IEC)-approved informed consent and be willing to
             make the required study visits and follow instructions while enrolled in the study.
             For subjects ≥7 years of age, assent will be obtained if required by the institution.
             For subjects &lt; 7 years of age, legal assent is not reasonable to obtain.

          2. Severe (factor IX activity ≤2 IU/dL) hemophilia B subjects currently on-demand therapy
             with a minimum of 2 bleeding episodes requiring factor IX therapy over the preceding 6
             months or 4 bleeding episodes over the preceding 12 months; subjects on prophylaxis
             with a bleeding pattern similar to that above demonstrated prior to starting
             prophylaxis

          3. Immunocompetent (CD4 count &gt;400/mm3) and not receiving immune modulating or
             chemotherapeutic agents

          4. Previously treated patients with a minimum of 50 exposure days to a factor IX
             preparation

          5. Platelet count at least 150,000/mm3

          6. Liver function: alanine transaminase [ALT] and aspartate transaminase [AST] ≤2 times
             the upper limit of the normal range

          7. Total bilirubin ≤1.5 times the upper limit of the normal range

          8. Renal function: serum creatinine ≤1.25 times the upper limit of the normal range

          9. Willingness to participate in the trial for approximately 6 months (50 exposures)

         10. Age ≤12 years

         11. Hemoglobin ≥7 g/dL at the time of the blood draw

        Exclusion Criteria:

          1. History of factor IX inhibitor ≥0.6 Bethesda units (BU)

          2. Existence of another coagulation disorder

          3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular
             coagulation (DIC)

          4. Use of an investigational drug within 30 days prior to study entry

          5. On medications that could impact hemostasis, such as aspirin

          6. History of poor compliance, a serious medical or social condition, or any other
             circumstance that, in the opinion of the investigator, would interfere with
             participation or compliance with the study protocol

          7. History of adverse reaction to either plasma-derived factor IX or recombinant factor
             IX that interfered with the subject's ability to treat bleeding episodes with a factor
             IX product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RUSH University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf States Hemophilia &amp; Thrombophilia Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMRI Hospital, Institute of Haematology &amp; Transfusion Medicine</name>
      <address>
        <city>Kolkata</city>
        <zip>700073</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College and Hospital</name>
      <address>
        <city>Ludhiana</city>
        <zip>141008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Centre Pvt. Ltd. Jehangir Hospital Premises</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahyadri Speciality Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhailal Amin General Hospital</name>
      <address>
        <city>Vadodara</city>
        <zip>390003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <results_first_submitted>February 28, 2019</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2019</results_first_posted>
  <disposition_first_submitted>January 10, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 10, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 8, 2019</disposition_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant Factor IX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IB1001</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pharmacokinetic Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IB1001</title>
          <description>PK study and Treatment Study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 to 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 11 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Infusions Required for Bleed Control</title>
        <time_frame>Treatment Study: at least 50 ED (approximately 6 months); actual mean subject duration: 39.7 ± 12.4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>Treatment phase: Prophylaxis treatment (n=8) and on demand treatment (n=1)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Required for Bleed Control</title>
          <units>Number of Infusions</units>
          <param>Count of Units</param>
          <units_analyzed>Number of Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 infusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 infusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 infusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 infusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 infusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 infusions</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (0-inf)</title>
        <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>PK phase</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (0-inf)</title>
          <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
          <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
          <units>IU*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1062" spread="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life</title>
        <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>PK phase</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life</title>
          <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
          <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration (Max)</title>
        <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>PK phase</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration (Max)</title>
          <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
          <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery</title>
        <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>PK phase</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery</title>
          <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
          <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
          <units>IU/dL per IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance</title>
        <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>PK phase</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance</title>
          <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
          <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
          <units>mL/(kg*hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Steady State)</title>
        <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>PK phase</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Steady State)</title>
          <description>Factor IX levels were assessed at the following time points:
Pre-infusion, post-infusion at 15-30 min, 4-6 hours, 24-26 hours, 68-72 hours</description>
          <population>9 subjects completed the PK phase. Only 6 subjects had adequate data for formal PK analysis.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" spread="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Bleed Rate</title>
        <description>Measure was assessed during the Treatment Study</description>
        <time_frame>Treatment Study: at least 50 ED (approximately 6 months); actual mean subject duration: 41.7+/- 11.7 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>Treatment study for those receiving prophylaxis treatment (n=8)</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleed Rate</title>
          <description>Measure was assessed during the Treatment Study</description>
          <units>bleeds/year</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IB1001</title>
          <description>IB1001 Safety population includes all subjects who received at least one dose of IB1001</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to a small number of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David Schaaf</name_or_title>
      <organization>Aptevo Therapeutics</organization>
      <phone>206-859-6655</phone>
      <email>schaafd@apvo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

